The author is a Reuters Breakingviews columnist. The opinions expressed are his own.

By Liam Proud

LONDON, June 26 (Reuters Breakingviews) - The €46 bln German conglomerate won a US Supreme Court victory related to weedkiller Roundup. It stops a host of claims under state law. As the litigation saga inches to a close, investors can start to ask normal financial questions again, like whether it's time for a breakup.

Full view will be published shortly.

Follow Liam Proud on Bluesky and LinkedIn.

CONTEXT NEWS

The U.S. Supreme Court on June 25 reined in thousands of lawsuits pursued in state courts accusing Bayer of failing to warn users that the active ingredient in its Roundup weedkiller causes cancer.

The justices in a 7-2 decision overturned a jury verdict in Missouri awarding $1.25 million to a man named John Durnell who said he was diagnosed with non-Hodgkin lymphoma after years of exposure to glyphosate in Roundup. The Supreme Court agreed with Bayer that a U.S. law that governs pesticides precludes so-called failure-to-warn claims, that are brought under state law, from moving forward in court.

Conservative Justice Brett Kavanaugh, who authored the ruling, said the U.S. Environmental Protection Agency has concluded glyphosate does not cause cancer and has not required a cancer warning on Roundup.

Bayer's Germany-listed shares closed roughly 19% higher on June 25.